Non Viral Delivery Systems and LNP Platforms for Genetic Therapies Market Current Trends Analysis 2026 to 2035
Market Segmentation:
Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market by Delivery Platform Type
- Lipid Nanoparticles (LNPs)
- Cell-Targeted LNPs (ctLNPs)
- Polymeric Nanoparticles
- DNA-Based Nanocarriers
Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market by Nucleic Acid Cargo
- mRNA
- siRNA
- miRNA
- Antisense Oligonucleotides (ASOs)
Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market by Application Area
- mRNA Therapeutics
- RNA Interference (RNAi) Therapies
- In Vivo Gene Editing
- Gene Replacement Therapies
- Protein Replacement via mRN
Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market by Target Tissue / Organ
- Liver
- Lung (Inhaled / Nebulized Delivery)
- Immune Cells
- Central Nervous System (CNS)
Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market by Route of Administration
- Intravenous (IV)
- Subcutaneous (SC)
- Intramuscular (IM)
- Inhalation / Pulmonary
Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market By Stage of Development
- Commercial / Approved Products
- Phase III
- Phase II
Global Non-Viral Delivery Systems & LNP Platforms for Genetic Therapies Market by End-User
- Biopharmaceutical Companies
- Gene Therapy Developers
- RNA Therapeutics Companies
- Academic & Research Institutes
By Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Snapshot
Chapter 4. Global Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2026-2035
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2026)
4.9. Use/impact of AI on Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Industry Trends
4.10. Global Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
Chapter 5. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 1: By Delivery Platform Type, Estimates & Trend Analysis
5.1. Market Share by Delivery Platform Type, 2025 & 2035
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following Delivery Platform Type:
5.2.1. Lipid Nanoparticles (LNPs)
5.2.2. Cell-Targeted LNPs (ctLNPs)
5.2.3. Polymeric Nanoparticles
5.2.4. DNA-Based Nanocarriers
5.2.5. Extracellular Vesicles (Exosomes / EVs)
5.2.6. Hybrid Non-Viral Delivery Systems
Chapter 6. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 2: By Nucleic Acid Cargo,
Estimates & Trend Analysis
6.1. Market Share by Nucleic Acid Cargo, 2025 & 2035
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following Nucleic Acid Cargo:
6.2.1. mRNA
6.2.2. siRNA
6.2.3. miRNA
6.2.4. Antisense Oligonucleotides (ASOs)
6.2.5. Plasmid DNA
6.2.6. Circular RNA (circRNA / oRNA)
6.2.7. CRISPR/Cas Components (gRNA, mRNA, RNPs)
6.2.8. Base Editing & Prime Editing Payloads
Chapter 7. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 3: Application Area, Estimates & Trend Analysis
7.1. Market Share by Application Area, 2025 & 2035
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following Application Area:
7.2.1. mRNA Therapeutics
7.2.2. RNA Interference (RNAi) Therapies
7.2.3. In Vivo Gene Editing
7.2.4. Gene Replacement Therapies
7.2.5. Protein Replacement via mRNA
7.2.6. Cancer Genetic Therapies
7.2.7. Rare & Ultra-Rare Genetic Disorders
Chapter 8. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 4: Target Tissue / Organ, Estimates & Trend Analysis
8.1. Market Share by Target Tissue / Organ, 2025 & 2035
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following Target Tissue / Organ:
8.2.1. Liver
8.2.2. Lung (Inhaled / Nebulized Delivery)
8.2.3. Immune Cells
8.2.4. Central Nervous System (CNS)
8.2.5. Peripheral Nervous System
8.2.6. Muscle
8.2.7. Tumor / Solid Oncology Targets
8.2.8. Multi-Organ / Systemic Delivery
Chapter 9. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 5: By Route of Administration, Estimates & Trend Analysis
9.1. Market Share by Route of Administration, 2025 & 2035
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following Route of Administration:
9.2.1. Intravenous (IV)
9.2.2. Subcutaneous (SC)
9.2.3. Intramuscular (IM)
9.2.4. Inhalation / Pulmonary
9.2.5. Others (Intratumoral/Intrathecal)
Chapter 10. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 6: By Stage of Development, Estimates & Trend Analysis
10.1. Market Share by Stage of Development, 2025 & 2035
10.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following Stage of Development:
10.2.1. Commercial / Approved Products
10.2.2. Phase III
10.2.3. Phase II
10.2.4. Phase I
10.2.5. Preclinical / Discovery Platforms
Chapter 11. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 7: By End-User, Estimates & Trend Analysis
11.1. Market Share by End-User, 2025 & 2035
11.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2022 to 2035 for the following End-User:
11.2.1. Biopharmaceutical Companies
11.2.2. Gene Therapy Developers
11.2.3. RNA Therapeutics Companies
11.2.4. Academic & Research Institutes
11.2.5. Strategic Platform Partners
Chapter 12. Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Segmentation 8: Regional Estimates & Trend Analysis
12.1. Global Tumour-Infiltrating Lymphocyte (TIL) Therapy Market, Regional Snapshot 2025 & 2035
12.2. North America
12.2.1. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
12.2.1.1. US
12.2.1.2. Canada
12.2.2. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Platform Type, 2022-2035
12.2.3. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Nucleic Acid Cargo, 2022-2035
12.2.4. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2022-2035
12.2.5. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Target Tissue / Organ, 2022-2035
12.2.6. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
12.2.7. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development, 2022-2035
12.2.8. North America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035
12.3. Europe
12.3.1. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
12.3.1.1. Germany
12.3.1.2. U.K.
12.3.1.3. France
12.3.1.4. Italy
12.3.1.5. Spain
12.3.1.6. Rest of Europe
12.3.2. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Platform Type, 2022-2035
12.3.3. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Nucleic Acid Cargo, 2022-2035
12.3.4. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2022-2035
12.3.5. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Target Tissue / Organ, 2022-2035
12.3.6. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
12.3.7. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development, 2022-2035
12.3.8. Europe Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035
12.4. Asia Pacific
12.4.1. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2022-2035
12.4.1.1. India
12.4.1.2. China
12.4.1.3. Japan
12.4.1.4. Australia
12.4.1.5. South Korea
12.4.1.6. Hong Kong
12.4.1.7. Southeast Asia
12.4.1.8. Rest of Asia Pacific
12.4.2. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Platform Type, 2022-2035
12.4.3. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Nucleic Acid Cargo, 2022-2035
12.4.4. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2022-2035
12.4.5. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Target Tissue / Organ, 2022-2035
12.4.6. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
12.4.7. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development, 2022-2035
12.4.8. Asia Pacific Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035
12.5. Latin America
12.5.1. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2022-2035
12.5.1.1. Brazil
12.5.1.2. Mexico
12.5.1.3. Rest of Latin America
12.5.2. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Platform Type, 2022-2035
12.5.3. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Nucleic Acid Cargo, 2022-2035
12.5.4. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2022-2035
12.5.5. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Target Tissue / Organ, 2022-2035
12.5.6. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
12.5.7. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development, 2022-2035
12.5.8. Latin America Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035
12.6. Middle East & Africa
12.6.1. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Mn) Estimates and Forecasts by country, 2022-2035
12.6.1.1. GCC Countries
12.6.1.2. Israel
12.6.1.3. South Africa
12.6.1.4. Rest of Middle East and Africa
12.6.2. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Platform Type, 2022-2035
12.6.3. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Nucleic Acid Cargo, 2022-2035
12.6.4. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application Area, 2022-2035
12.6.5. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Target Tissue / Organ, 2022-2035
12.6.6. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2022-2035
12.6.7. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by Stage of Development, 2022-2035
12.6.8. Middle East & Africa Tumour-Infiltrating Lymphocyte (TIL) Therapy Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2022-2035
Chapter 13. Competitive Landscape
13.1. Major Mergers and Acquisitions/Strategic Alliances
13.2. Company Profiles
13.2.1. Acuitas Therapeutics
13.2.1.1. Business Overview
13.2.1.2. Key Product/Service
13.2.1.3. Financial Performance
13.2.1.4. Geographical Presence
13.2.1.5. Recent Developments with Business Strategy
13.2.2. Alnylam Pharmaceuticals
13.2.3. Arcturus Therapeutics
13.2.4. Beam Therapeutics
13.2.5. Code Biotherapeutics
13.2.6. CRISPR Therapeutics
13.2.7. CureAge Therapeutics
13.2.8. Editas Medicine
13.2.9. Evox Therapeutics
13.2.10. GenEdit
13.2.11. Genevant Sciences
13.2.12. Generation Bio
13.2.13. Genprex
13.2.14. Intellia Therapeutics
13.2.15. Moderna
13.2.16. NanoVation Therapeutics
13.2.17. Orna Therapeutics
13.2.18. ReCode Therapeutics
13.2.19. STRM.BIO
13.2.20. Vertex Pharmaceuticals
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Non Viral Delivery Systems and LNP Platforms for Genetic Therapies Market is estimated to grow at a 16.1% CAGR during the forecast period for 2026 to 2035.
Acuitas Therapeutics, Alnylam Pharmaceuticals, Arcturus Therapeutics, Beam Therapeutics, Code Biotherapeutics, CRISPR Therapeutics, CureAge Therapeutics, Editas Medicine, Evox Therapeutics, GenEdit, Genevant Sciences, Generation Bio, Genprex, Intellia Therapeutics, Moderna, NanoVation Therapeutics, Orna Therapeutics, ReCode Therapeutics, STRM.BIO, Vertex Pharmaceuticals.
By Delivery Platform Type, Nucleic Acid Cargo, Application Area, Target Tissue, Route of Administration, Stage of Development, End-User are the key segments of the Non Viral Delivery Systems and LNP Platforms for Genetic Therapies Market
North America region is leading the Non Viral Delivery Systems and LNP Platforms for Genetic Therapies Market.